OLEMA PHARMACEUTICALS, INC. Operating Lease, Payments
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Operating Lease, Payments of $313.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2026-06-30 was $313.00K, a 0.64% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2026-03-31 was $313.00K, a 1.29% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2025-12-31 was $302.00K, a 1.31% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2025-09-30 was $312.00K, a 2.97% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for fiscal 2025 was $1.23M, a 6.11% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for fiscal 2024 was $1.16M, a 5.61% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for fiscal 2023 was $1.23M, a 3.38% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. operating lease, payments for fiscal 2022 was $1.27M, a 28.95% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $313.00K 10-Q · filed 2026-08-10 | $625.00K 10-Q · filed 2026-08-10 | $928.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $313.00K 10-Q · filed 2026-05-12 | $615.00K derived: sum of 2 quarters · filed 2026-05-12 | $927.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $614.00K derived: sum of 2 quarters · filed 2026-03-16 | $925.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.23M 10-K · filed 2026-03-16 |
| 2025-09-30 | $312.00K 10-Q · filed 2025-11-10 | $623.00K derived: sum of 2 quarters · filed 2026-08-10 | $931.00K 10-Q · filed 2025-11-10 | $1.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $311.00K 10-Q · filed 2026-08-10 | $620.00K 10-Q · filed 2026-08-10 | $926.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $309.00K 10-Q · filed 2026-05-12 | $615.00K derived: sum of 2 quarters · filed 2026-05-12 | $918.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.21M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $609.00K derived: sum of 2 quarters · filed 2026-03-16 | $902.00K derived: sum of 3 quarters · filed 2026-03-16 | $1.16M 10-K · filed 2026-03-16 |
| 2024-09-30 | $303.00K 10-Q · filed 2025-11-10 | $596.00K derived: sum of 2 quarters · filed 2025-11-10 | $856.00K 10-Q · filed 2025-11-10 | $1.12M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $293.00K 10-Q · filed 2025-08-11 | $553.00K 10-Q · filed 2025-08-11 | $816.00K derived: sum of 3 quarters · filed 2025-08-11 | $1.13M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $260.00K 10-Q · filed 2025-05-13 | $523.00K derived: sum of 2 quarters · filed 2025-05-13 | $838.00K derived: sum of 3 quarters · filed 2025-05-13 | $1.17M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $578.00K derived: sum of 2 quarters · filed 2025-03-18 | $905.00K derived: sum of 3 quarters · filed 2025-03-18 | $1.23M 10-K · filed 2025-03-18 |
| 2023-09-30 | $315.00K 10-Q · filed 2024-11-12 | $642.00K derived: sum of 2 quarters · filed 2024-11-12 | $968.00K 10-Q · filed 2024-11-12 | $1.29M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $327.00K 10-Q · filed 2024-08-06 | $653.00K 10-Q · filed 2024-08-06 | $976.00K derived: sum of 3 quarters · filed 2024-08-06 | $1.29M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $326.00K 10-Q · filed 2024-05-08 | $649.00K derived: sum of 2 quarters · filed 2024-05-08 | $968.00K derived: sum of 3 quarters · filed 2024-05-08 | $1.28M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $642.00K derived: sum of 2 quarters · filed 2024-03-11 | $959.00K derived: sum of 3 quarters · filed 2024-03-11 | $1.27M 10-K · filed 2024-03-11 |
| 2022-09-30 | $319.00K 10-Q · filed 2022-11-08 | $636.00K derived: sum of 2 quarters · filed 2022-11-08 | $951.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $317.00K 10-Q · filed 2022-08-09 | $632.00K 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $315.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $988.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |